Onderzoeker
Sam Hofmans
- Trefwoorden:Farmacie
- Disciplines:Ontdekking en evaluatie van biomarkers, Ontdekking en evaluatie van geneesmiddelen, Medicinale chemie, Medicinale producten, Farmaceutische analyse en kwaliteitszorg, Farmaceutica, Farmacognosie en fytochemie, Farmacologie, Farmacotherapie, Toxicologie en toxinologie, Andere farmaceutische wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Medicinale chemie (UAMC) (Onderzoeksgroep)
Lid
Vanaf1 sep 2012 → 30 sep 2017
Publicaties
1 - 8 van 8
- Inhibitors targeting RIPK1/RIPK3(2020)
Auteurs: Sofie Martens, Sam Hofmans, Wim Declercq, Koen Augustyns, Peter Vandenabeele
Pagina's: 209 - 224 - Tozasertib analogues as inhibitors of necroptotic cell death(2018)
Auteurs: Sam Hofmans, Lars Devisscher, Sofie Martens, Dries Van Rompaey, Kenneth Goossens, Tatyana Divert, Wim Nerinckx, Nozomi Takahashi, Hans De Winter, Pieter Van Der Veken, et al.
Pagina's: 1895 - 1920 - Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy(2018)
Auteurs: Lars Devisscher, Samaya Van Coillie, Sam Hofmans, Dries Van Rompaey, Kenneth Goossens, Eline Meul, Hans De Winter, Pieter Van Der Veken, Peter Vandenabeele, Tom Vanden Berghe, et al.
Pagina's: 10126 - 10140 - Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis(2018)
Auteurs: Isabelle Coornaert, Sam Hofmans, Lars Devisscher, Koen Augustyns, Pieter Van Der Veken, Guido De Meyer, Wim Martinet
Pagina's: 477 - 488 - RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680)(2018)
Auteurs: Sofie Martens, Vera Goossens, Lars Devisscher, Sam Hofmans, Polien Claeys, Marnik Vuylsteke, Nozomi Takahashi, Koen Augustyns, Peter Vandenabeele
- Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury(2017)
Auteurs: Sofie Martens, Manhyung Jeong, Wulf Tonnus, Friederike Feldmann, Sam Hofmans, Vera Goossens, Nozomi Takahashi, Jan Hinrich Braesen, Eun-Woo Lee, Pieter Van Der Veken, et al.
- Identification, lead optimization and validation of necroptosis and ferroptosis inhibitors(2017)
Auteurs: Sam Hofmans
Aantal pagina's: 334 - Novel ferroptosis inhibitors with improved potency and ADME properties(2016)
Auteurs: Sam Hofmans, Tom Vanden Berghe, Lars Devisscher, Behrouz Hassannia, Sophie Lyssens, Jurgen Joossens, Pieter Van Der Veken, Peter Vandenabeele, Koen Augustyns
Pagina's: 2041 - 2053
Patenten
1 - 5 van 5
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)